clinical trial · NCT07788807
A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
Surmount Services, Inc.·phase1·recruiting·n = 18
Healthy SubjectsAdalimumabGuselkumabSDL-001
brief summary
This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation. The study endpoints chosen for this study are commonly used for evaluating the safety, tolerability, and PK of single doses of IPs. No interim analysis is planned.
started
Oct 7, 2026
primary completion
Nov 20, 2026
completion
Dec 30, 2026
last updated
Nov 9, 2026
official title
An Open-label, Phase 1, Pharmacokinetic Study of a Single Dose of Transcolonically Administered Adalimumab and Guselkumab in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol